Ask VialBase
growth · hormone

Sermorelin

Also known as: Sermorelin acetate, Geref, GRF 1-29, GHRH(1-29)NH2
FDA: Previously FDA-approved as Geref Diagnostic (1997) for GH deficiency diagnosis; withdrawn from market 2008 WADA: Prohibited at all times

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 residues of human growth hormone-releasing hormone (GHRH). It is the shortest fully functional fragment of GHRH, retaining full biological activity at the pituitary GHRH receptor. Unlike exogenous GH, sermorelin preserves the hypothalamic-pituitary feedback loop, producing physiological pulsatile GH release rather than supraphysiological spikes. Previously FDA-approved as Geref Diagnostic for evaluating pituitary GH reserve, it was voluntarily withdrawn from market in 2008 (not for safety reasons). It remains one of the most widely compounded peptides for age-related GH decline. For educational purposes only. Not medical advice. Sermorelin binds to the

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight 3,357.93 Da
Half-life 10-20 minutes
CAS number —
Route Subcutaneous · Intravenous subcutaneous preferred
02

Mechanism

Binds GHRH receptors on anterior pituitary somatotrophs, stimulating endogenous GH synthesis and pulsatile release via cAMP/PKA signaling

03

Dosing

DOSE RANGE 100–300 mcg
FREQUENCY 1x daily at bedtime
CYCLE LENGTH 3-6 months

Administer on empty stomach, 30 min before sleep to align with natural GH pulse. 5 days on / 2 days off cycling is common.

04

Research summary

Study Type Year Key Finding
Injectable Peptide Therapy in Regenerative Medicine and Sports Performance Narrative review 2026 Reviews BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu
Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss Narrative review 2026 Weight loss from any method is accompanied by lean body mass loss
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance Narrative review 2026 Sermorelin is among 12 peptides reviewed for musculoskeletal applications
05

Stacking & interactions

GHRH + GHRP synergy for amplified GH pulse

Extended GHRH signaling (CJC-1295 has longer half-life)

Alternative GHRH analog with more clinical data

Metabolic optimization stack

06

Sourcing

Current prices

Updated today

5mg

10mg

Size unspecified

Stocks this compound Third-party tested Public COAs

Save 50% via this link — discount auto-applied at checkout.

Stocks this compound Third-party tested Public COAs
Stocks this compound Third-party tested Public COAs

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

Also vetted at
What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • IGF-1
  • Fasting Glucose
  • Fasting Insulin
  • CMP
  • CBC
DURING CYCLE
  • IGF-1
  • Fasting Glucose
  • Fasting Insulin
POST-CYCLE
  • IGF-1
  • Fasting Glucose
Safety & Regulatory Status
FDA STATUS Previously FDA-approved as Geref Diagnostic (1997) for GH deficiency diagnosis; withdrawn from market 2008. Now available via 503A/503B compounding.
WADA STATUS Prohibited at all times (S2 - Peptide Hormones, Growth Factors)

Regulatory status for Sermorelin may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

References

  1. Multiple authors (Keck School of Medicine of USC). Injectable Peptide Therapy in Regenerative Medicine and Sports Performance. American Journal of Sports Medicine (2026). PMID: 41490200
  2. Multiple authors. Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss. Journal of Clinical Medicine (2026). PMID: 41598480
  3. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine (2026). PMID: 41966639